The challenge of standardizing the measurement of an imprecise biomarker like HRD

The safety and effectiveness profile of a drug can be improved by using it in patients where that drug is most likely to be effective but determining whether a cancer is HRD-positive is neither trivial nor precise. How characteristics are measured, integrated, and distilled into a final determination of whether HRD is present or absent varies, which can create uncertainty around treatment options and enrollment into clinical trials. 

 

 

 

 

 

In order to enable more standardized reporting of HRD and to enable the assessment of HRD assays, we created a set of characterized reference materials composed of HRD negative, borderline, and positive tumor/normal matched cell lines that were analyzed using both array-based and next generation sequencing-based assays in order to determine chromosomal changes across their genomes. Download this poster presented at AACR 2022 to learn more.